15 Innovative Healthcare Stocks to Buy According to Analysts

7. Doximity, Inc. (NYSE:DOCS)

Price Target Upside: 44.67%

The stock given seventh position on our list of best healthcare stocks is Doximity, Inc. (NYSE:DOCS).

TheFly reported on February 9 that Canaccord Genuity upgraded DOCS from Hold to Buy and lowered the price target to $34 from $48. The post-earnings selloff, according to the firm, was an overreaction to immediate worries about how policy and pricing uncertainties might impact pharmaceutical budgets. It was wise to draw a line and upgrade the company, according to Canaccord, which also predicted that DOCS shares would rise sharply over the course of the upcoming year as pharmaceutical budgets level off, offering a longer-term buying opportunity.

Moreover, Doximity, Inc. (NYSE: DOCS) announced its fiscal Q3 2026 results on February 5. The company’s revenue for the quarter ending December 31, 2025, was $185.1 million, a 10% rise over the previous year. While net income reached $61.6 million, suggesting a 33% margin, adjusted EBITDA climbed 9% to $111.4 million, with margins staying at 60%. According to the company, platform engagement reached all-time highs, with 720,000 active users for workflow solutions and over 300,000 people using AI features. CEO Jeff Tangney claims that platform utility has increased as a result of AI integration.

In addition, the company authorized a $500 million stock repurchase program, which underscores confidence in long-term value creation. DOCS also provided guidance for Q4 and full fiscal 2026, projecting revenues of approximately $643 million and adjusted EBITDA near $356 million.

Doximity, Inc. (NYSE:DOCS) is a U.S. digital healthcare platform connecting medical professionals with secure networking, telehealth, AI‑powered workflow tools, and clinical insights. It innovates by embedding AI, telemedicine, and productivity tools into a unified physician‑centric ecosystem that streamlines care delivery, communication, and administrative tasks.